Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 509 Next >>

Filter Applied: safety (Click to remove)

Progress Toward Mitigating Disability Progression in Multiple Sclerosis
NEJM 392:1966-1968, Calabresi,P.A., 2025

Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke
NEJM 380:1795-1803,1865, Ma, H.,et al, 2019

Endovascular Therapy for Ischemic Stroke with Perfusion-Imaging Selection
NEJM 372:1009-1018, Campbell, B.C.V.,et al, 2015

Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke
NEJM 372:1019-1030, Goyal, M.,et al, 2015

Characteristics of Lumbar Disc Herniation with Exacerbation of Presentation Due to Spinal Manipulative Therapy
Medicine 94:e661, Huang, S.L.,et al, 2015

Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke
NEJM 372:DOI:10.1056/NEJMoa1415061, DOI:10.1056 NEJM e1503217, Saver, J.L.,et al, 2015

Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke
NEJM 372:DOI:10.1056 NEJMoa1503780, DOI:1056NEJM e1503217, Jovin, T.G.,et al, 2015

Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke
NEJM 372:2285-2295,2347, Saver, J.L.,et al, 2015

Thrombectomy within 8 hours after Symptom Onset in Ischemic Stroke
NEJM 372:2296-2306,2347, Jovin, T.G.,et al, 2015

Effect of high-dose Simvastatin on Brain Atrophy and Disability in Secondary Progressive Multiple Sclerosis (MS-STAT): A Randomised, Placebo-Controlled, Phase 2 Trial
Lancet 383:2213-2221, Chataway, J.,et al, 2014

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
NEJM 367:1098-1106,1149, Gold, R.,et al, 2012

Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011

Decompressive Craniectomy in Diffuse Traumatic Brain Injury
NJM 364:1493-1502, Cooper, D.J.,et al, 2011

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
NEJM 365:1293-1303, OConnor, P.,et al, 2011

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
NEJM 362:416-426, 456, Giovannoni,G.,et al, 2010

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
NEJM 362:387-401, 456, Kappos, L.,et al, 2010

Immunologic, Clinical, and Radiologic Status 14 Months After Cessation of Natalizumab Therapy
Neurol 72:396-401,392, Stuve,O.,et al, 2009

Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis
Arch Neurol 65:1044-1051, Krishnan,C.,et al., 2008

Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025

FUTURE-AI: International Consensus Guideline for Trustworthy and Deployable Artificial Intelligence in Healthcare
BMJ 388:e081554, Lekadir,K.,et al, 2025

Commonly Used Interventional Procedures for Non-Cancer Chronic Spine Pain: A Clinical Practice Guideline
BMJ 388:e079970, Busse,J.W.,et al, 2025

Embolization of the Middle Meningeal Artery for Chronic Subdural Hematoma
NEJM 392:855-864, 918, Fiorella,D.,et al, 2025

Calcitonin Gene-Related Peptide-Targeted Therapy in Migraine: Current Role and Future Perspectives
Lancet 405:1014-1026, Versijpt,J.,et al, 2025

Inebilizumab for Treatment of IgG4-Related Disease
NEJM 392:1168-1177, Stone,J.H.,et al, 2025

Beyond Glucocorticoids for IgG4-Related Disease
NEJM 392:1232-1233, Spiera,R., 2025

Alteplase for Posterior Circulation Ischemic Stropke at 4.5 to 24 Hours
NEJM 392:1288-1296, Yan,S.,et al, 2025

Left Atrial Appendage Closure After Ablation for Atrial Fibrillation
NEJM 392:1277-1287, Wazni,O.M.,et al, 2025

Long-Term Effects of Antidarsagene Autotemcel for Metachromatic Leukodystrophy
NEJM 392:1609-1620, Fumagalli,F.,et al, 2025

Validation of an Artificial Intelligence-Powered Virtual Assistant for Emergency Triage in Neurology
Neurologist 30:155-163, Alessandro,L.,et al, 2025

General AI May Revolutionize Neurology 0 Or It Might be Bad
JAMA Neurol doi 10.1001/JAMANEUROL.2025.0905, Westover,M.B. & Westover,A.M., 2025

Upadacitinib - An Up-and-Comer for Treatment of Giant-Cell Arteritis
NEJM 392:2062-2064, Koster,M.J. & Warrington,K.J., 2025

Patent Foramen Ovale Management for Secondary Stroke Prevention:State-of-the-Art Appraisal of Current Evidence
Stroke 55:236-247, Sposato,L.A.,et al, 2024

Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024

Inhibition of CD40L with Frexalimab in Multiple Sclerosis
NEJM 390:589-600, 662, Vermersch,P.,et al, 2024

Tenecteplase for Stroke - Opening the Window?
NEJM 390:760-761, Leifer,D.,, 2024

Transcarotid Arter Revascularization Expanding Our Arsenal for the Management of Symptomatic Carotid Artery Stenosis
Stroke 55:931-933, Palaiodimou,L, 2024

Treatment Modalities and Outcomes in Brainstem Cavernous Malformations: A Large Multicenter Observational Cohort Study
Stroke 55:1151-1160, Lu,J.,et al, 2024

Mechanical Thrombectomy in Anticoagulated Patients with Acute Ischemic Stroke, A Meta-Analysis
Neurologist 29:194-203, Zhang,H.L.,et al, 2024

Small Step or Giant Leap? Expanding the Acute Stroke Thrombolysis Window to 24 Hour
NEJM 391:273-275, Lee,V.H., 2024

Timing of Anticoagulation Resumption and Risk of Ischemic and Hemorrhagic Complications in Patients with ICH and Mechanical Heart Valves
Neurol 103:e209664, Sakusic,A.,et al, 2024

Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia
NEJM 391:1015-1027, Al-Samkari,H.,et al, 2024

Intravenous Thrombolysis in Patients with Cervical Artery Dissection
Neurol 103:e209843, Shu,L.,et al, 2024

Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine, A Phase 4, Randomized, Placebo-Controlled Trial
JAMA Neurol 81:1140-1149, Tepper,S.J.,et al, 2024

How Patients Are Using AI
BMJ 387:q2393, Stokel-Walker,C., 2024

Safety and Efficacy of Staged, Bilateral Focused Ultrasound Thalamotomy in Essential Tremor, An Open-Label Clinical Trial
JAMA Neurol 81:939-946, Kaplitt,M.G.,et al, 2024

Effect of IV Thrombolysis With Alteplase in Patients with Vessel Occlusion in the WAKE-UP Trial
Neurol 104:e209871, Galinovic,I.,et al, 2024

Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023

Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinsons Disease
NEJM 388:683-693, 759, Krishna,V.,et al, 2023

Artificial Intelligence and Machine Learning in Clinical Medicine, 2023
NEjM 388:1201-1208,1220, Haug,C.H. & Drazen,J.M., 2023



Showing articles 0 to 50 of 509 Next >>